1. Betamethasone Exposure and Neonatal Respiratory Morbidity Among Late Preterm Births by Planned Mode of Delivery and Gestational Age.
- Author
-
Clapp MA, Li S, Cohen JL, Gyamfi-Bannerman C, Knudsen AB, Lorch SA, Thaweethai T, Wright JD, Kaimal AJ, and Melamed A
- Subjects
- Humans, Female, Pregnancy, Infant, Newborn, Adult, Delivery, Obstetric, Glucocorticoids administration & dosage, Glucocorticoids adverse effects, Respiratory Distress Syndrome, Newborn prevention & control, Respiratory Distress Syndrome, Newborn epidemiology, Cesarean Section statistics & numerical data, Infant, Premature, Betamethasone administration & dosage, Betamethasone adverse effects, Gestational Age, Premature Birth epidemiology, Premature Birth prevention & control
- Abstract
Objective: To estimate the effect of late preterm antenatal steroids on the risk of respiratory morbidity among subgroups of patients on the basis of the planned mode of delivery and gestational age at presentation., Methods: This was a secondary analysis of the ALPS (Antenatal Late Preterm Steroid) Trial, a multicenter trial conducted within the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network of individuals with singleton gestations and without preexisting diabetes who were at high risk for late preterm delivery (34-36 weeks of gestation). We fit binomial regression models to estimate the risk of respiratory morbidity, with and without steroid administration, by gestational age and planned mode of delivery at the time of presentation. We assumed a homogeneous effect of steroids on the log-odds scale, as was reported in the ALPS trial. The primary outcome was neonatal respiratory morbidity, as defined in the ALPS Trial., Results: The analysis included 2,825 patients at risk for late preterm birth. The risk of respiratory morbidity varied significantly by planned mode of delivery (adjusted risk ratio [RR] 1.90, 95% CI, 1.55-2.33 for cesarean delivery vs vaginal delivery) and week of gestation at presentation (adjusted RR 0.56, 95% CI, 0.50-0.63). For those planning cesarean delivery and presenting in the 34th week of gestation, the risk of neonatal respiratory morbidity was 39.4% (95% CI, 30.8-47.9%) without steroids and 32.0% (95% CI, 24.6-39.4%) with steroids. In contrast, for patients presenting in the 36th week and planning vaginal delivery, the risk of neonatal respiratory morbidity was 6.9% (95% CI, 5.2-8.6%) without steroids and 5.6% (95% CI, 4.2-7.0%) with steroids., Conclusion: The absolute risk difference of neonatal respiratory morbidity between those exposed and those unexposed to late preterm antenatal steroids varies considerably by gestational age at presentation and planned mode of delivery. Because only communicating the relative risk reduction of antenatal steroids for respiratory morbidity may lead to an inaccurate perception of benefit, more patient-specific estimates of risk expected with and without treatment may inform shared decision making., Competing Interests: Financial Disclosure Mark A. Clapp serves as a medical advisory board member with private equity in Delfina Health, outside the submitted work. Jason D. Wright has received research funding from Merck and honoraria from UpToDate. Cynthia Gyamfi-Bannerman reports grants from NHLBI, NICHD, and NIHMD and has received research funding from HealthCore Inc/SERA Prognostics, Inc. and MIRVIE, Inc. Alexander Melamed reports grants from the National Center for Advancing Translational Sciences, the National Cancer Institute, the Conquer Cancer-The ASCO Foundation, and the Department of Defense outside the submitted work. Dr. Melamed has also served as an advisor for AstraZeneca. The other authors did not report any potential conflicts of interest., (Copyright © 2024 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF